152 related articles for article (PubMed ID: 12214668)
1. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy.
Patterson LH
Drug Metab Rev; 2002 Aug; 34(3):581-92. PubMed ID: 12214668
[TBL] [Abstract][Full Text] [Related]
2. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
3. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug.
Raleigh SM; Wanogho E; Burke MD; McKeown SR; Patterson LH
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):763-7. PubMed ID: 9845092
[TBL] [Abstract][Full Text] [Related]
4. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug.
Raleigh SM; Wanogho E; Burke MD; Patterson LH
Xenobiotica; 1999 Nov; 29(11):1115-22. PubMed ID: 10598746
[TBL] [Abstract][Full Text] [Related]
5. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
Patterson LH
Cancer Metastasis Rev; 1993 Jun; 12(2):119-34. PubMed ID: 8375016
[TBL] [Abstract][Full Text] [Related]
6. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.
McCarthy HO; Yakkundi A; McErlane V; Hughes CM; Keilty G; Murray M; Patterson LH; Hirst DG; McKeown SR; Robson T
Cancer Gene Ther; 2003 Jan; 10(1):40-8. PubMed ID: 12489027
[TBL] [Abstract][Full Text] [Related]
7. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson LH; McKeown SR
Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
[TBL] [Abstract][Full Text] [Related]
8. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
Albertella MR; Loadman PM; Jones PH; Phillips RM; Rampling R; Burnet N; Alcock C; Anthoney A; Vjaters E; Dunk CR; Harris PA; Wong A; Lalani AS; Twelves CJ
Clin Cancer Res; 2008 Feb; 14(4):1096-104. PubMed ID: 18281542
[TBL] [Abstract][Full Text] [Related]
10. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH
Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844
[TBL] [Abstract][Full Text] [Related]
11. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
Yakkundi A; McErlane V; Murray M; McCarthy HO; Ward C; Hughes CM; Patterson LH; Hirst DG; McKeown SR; Robson T
Cancer Gene Ther; 2006 Jun; 13(6):598-605. PubMed ID: 16410820
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ
Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207
[TBL] [Abstract][Full Text] [Related]
13. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
Trédan O; Garbens AB; Lalani AS; Tannock IF
Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
[TBL] [Abstract][Full Text] [Related]
14. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.
Nishida CR; Lee M; de Montellano PR
Mol Pharmacol; 2010 Sep; 78(3):497-502. PubMed ID: 20566689
[TBL] [Abstract][Full Text] [Related]
15. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.
McKeown SR; Hejmadi MV; McIntyre IA; McAleer JJ; Patterson LH
Br J Cancer; 1995 Jul; 72(1):76-81. PubMed ID: 7599069
[TBL] [Abstract][Full Text] [Related]
16. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.
Atkinson SJ; Loadman PM; Sutton C; Patterson LH; Clench MR
Rapid Commun Mass Spectrom; 2007; 21(7):1271-6. PubMed ID: 17340571
[TBL] [Abstract][Full Text] [Related]
17. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
McErlane V; Yakkundi A; McCarthy HO; Hughes CM; Patterson LH; Hirst DG; Robson T; McKeown SR
J Gene Med; 2005 Jul; 7(7):851-9. PubMed ID: 15712360
[TBL] [Abstract][Full Text] [Related]
18. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.
Williams KJ; Albertella MR; Fitzpatrick B; Loadman PM; Shnyder SD; Chinje EC; Telfer BA; Dunk CR; Harris PA; Stratford IJ
Mol Cancer Ther; 2009 Dec; 8(12):3266-75. PubMed ID: 19996276
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the antiangiogenic potential of AQ4N.
O'Rourke M; Ward C; Worthington J; McKenna J; Valentine A; Robson T; Hirst DG; McKeown SR
Clin Cancer Res; 2008 Mar; 14(5):1502-9. PubMed ID: 18316575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
